PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and potential antitumor activity of weekly paclitaxel with concurrent radiation (RT) for locally advanced pancreatic and gastric cancer. PATIENTS AND METHODS: Thirty-four patients with locally advanced adenocarcinoma of the pancreas or stomach were studied. The initial dose of paclitaxel was 30 mg/m2 by 3-hour intravenous (I.V.) infusion repeated every week for 6 weeks with 50 Gy RT. Doses were escalated at 10-mg/m2 increments in successive cohorts of three new patients until dose-limiting toxicity was observed. RESULTS: The dose-limiting toxicities at 60 mg/m2/wk were abdominal pain within the RT field, nausea, and anorexia. Of 23 patients with assessable disease, 11 (seven with gastric, four with pancreatic cancer) had objective responses for an overall response rate of 48%. CONCLUSION: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paclitaxel and RT at the MTD of 50 mg/m2/wk is underway.
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and potential antitumor activity of weekly paclitaxel with concurrent radiation (RT) for locally advanced pancreatic and gastric cancer. PATIENTS AND METHODS: Thirty-four patients with locally advanced adenocarcinoma of the pancreas or stomach were studied. The initial dose of paclitaxel was 30 mg/m2 by 3-hour intravenous (I.V.) infusion repeated every week for 6 weeks with 50 Gy RT. Doses were escalated at 10-mg/m2 increments in successive cohorts of three new patients until dose-limiting toxicity was observed. RESULTS: The dose-limiting toxicities at 60 mg/m2/wk were abdominal pain within the RT field, nausea, and anorexia. Of 23 patients with assessable disease, 11 (seven with gastric, four with pancreatic cancer) had objective responses for an overall response rate of 48%. CONCLUSION: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paclitaxel and RT at the MTD of 50 mg/m2/wk is underway.
Authors: V K Mehta; G Fisher; J A Ford; J C Poen; M A Vierra; H Oberhelman; J Niederhuber; J A Bastidas Journal: J Gastrointest Surg Date: 2001 Jan-Feb Impact factor: 3.452
Authors: Alberto Biondi; Maria C Lirosi; Domenico D'Ugo; Valeria Fico; Riccardo Ricci; Francesco Santullo; Antonia Rizzuto; Ferdinando Cm Cananzi; Roberto Persiani Journal: World J Gastrointest Oncol Date: 2015-12-15
Authors: Anuja Jhingran; Lois M Ramondetta; Diane C Bodurka; Brian M Slomovitz; Jubilee Brown; Lawrence B Levy; Michael E Garcia; Patricia J Eifel; Karen H Lu; Thomas W Burke Journal: Gynecol Oncol Date: 2013-02-04 Impact factor: 5.482
Authors: Tyvin A Rich; Kathryn Winter; Howard Safran; John P Hoffman; Beth Erickson; Pramila R Anne; Robert J Myerson; Vivian Jm Cline-Burkhardt; Kimberly Perez; Christopher Willett Journal: Onco Targets Ther Date: 2012-08-23 Impact factor: 4.147
Authors: Luke P Legakis; Clare M Diester; Edward A Townsend; Ladan Karim-Nejad; Sidney Stevens Negus Journal: Behav Pharmacol Date: 2020-08 Impact factor: 2.277